HomepageEarnings Events Newsdesk 9 minutes ago Amgen Inc. (AMGN) Repatha® Cuts Risk Of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis Amgen Inc. (NASDAQ: AMGN) FY 2026 Other Release « Eli Lilly and Company (LLY) Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity Newsdesk:
